Prescient Design has joined Genentech's Research and Early Development organization (gRED) in order to apply their cutting-edge technology and machine learning approach to our drug discovery efforts. We believe that Prescient Design's platform and expertise, combined with our growing internal computational capabilities, can ultimately help us bring better medicines to patients faster.
Founded by computer science and computational biology faculty members at New York University and the Flatiron Institute, the Prescient Design team has extensive expertise in the machine learning. They are focused on applying this cutting-edge technology to drug discovery.
By bringing further advances in machine learning and artificial intelligence to Genentech, my goal is to help make the organization future-proof and develop potential medicines that treat diseases we haven’t been able to tackle.
Advanced Computation and Data Science
Computation and data science are enhancing every aspect of drug discovery and development. Explore how we are applying these methods to deliver breakthrough medicines to patients.